Glaxo Group Limited

Smithkline Beecham Corporation

Glaxco Group Limited

Alison Judith Redgrave

Christopher James Lunniss

Brian Edgar Looker

David George Allen

Julie Nicole Hamblin

Paul Spencer Jones

Suzanne Elaine Keeling

Brian Cox

Caroline Mary Cook

Heather Hobbs

Joanna Victoria Geden

Diane Mary Coe

Charlotte Jane Mitchell

Anthony William James Cooper

Mika Lindvall

Chuen Chan

Michael David Barker

Martin Redpath Johnson

Richard Peter Charles Cousins

Christopher David Edlin

John Edward Robinson

Thomas Davis Roper, Iv

Hazel Joan Dyke

David E Bays

Michael D Dowle

Istvan Kaldor

Colin David Eldred

Stephen Barry Guntrip

Stephen Swanson

Shiping Xie

Brian Evans

Frank Ellis

Ian Robert Baldwin

Caroline Whitworth

Michael David Woodrow

Stuart Holman

Anthony William Dean

Derek Peter Reynolds

Tracy Jane Redfern

Mika Kristian Lindvall

Sharon Lisa Gough

There are provided according to the invention novel compounds of formula (I)  or pharmaceutically acceptable salts thereof, wherein R, RRRand Rare as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

Quinoline derivatives as phosphodiesterase inhibitors

The invention relates to a compound of formula (I) or a salt thereof: wherein: Ris Calkyl, Cfluoroalkyl or &#x2014;(CH)OH; Ris a hydrogen atom (H), methyl or Cfluoroalkyl; Ris a hydrogen atom (H) or Calkyl; Ris optionally substituted branched Calkyl, optionally substituted Ccycloalkyl, optionally substituted mono-unsaturated-Ccycloalkenyl, optionally substituted phenyl, or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc): in which nand nindependently are 1 or 2; and Y is O, S, SO, or NR; and wherein Het is of sub-formula (i), (ii), (iii), (iv) or (v): The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.

Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors

The invention relates to a compound of formula (I) or a salt thereof: wherein: Ris Et, n-Pr, i-Pr, Cfluoroalkyl, or &#x2014;CHCHOH; wherein Ris methyl or ethyl; Ris H, methyl or ethyl; Ris H, methyl or ethyl, Ris H, methyl or ethyl, and Ris H or methyl, These compounds are PDE4 inhibitors.

[object Object]

Compounds of formula (I): and uses of such compounds are described.

Compounds for use as surfactants

Compounds of formula (I): or salts or solvate thereof, wherein:

A method for treating respiratory disorders comprises administering to a patient a pharmaceutical aerosol formulation comprising: (i) a compound of formula (I) 

Alkanoic acid derivatives

Compounds of formula (I) or a salt or solvate thereof, wherein:

Carboxylic acid compounds for use as surfactants

A pharmaceutical aerosol formulation that includes a particulate medicament, one or more fluorocarbon or hydrogen-containing fluorocarbon propellants and a compound of the general formula (I) or a salt or solvate thereof is disclosed, wherein wherein at least one substituent of formula B contains at least one fluorine atom and each Cfluoroalkyl- moiety contains one or more fluorine atoms but not more than 3 consecutive perfluorinated carbon atoms. Compounds of formula (I) and uses of such compounds are also disclosed.

Surfactant compounds and uses thereof

A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2a receptor are described.

2-(purin-9-yl)-Tetrahydrofuran-3,4-diol derivatives

A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2 receptor are described.

2-(Purin -9-yl)-tetrahydrofuran-3,4-diol derivatives

There are provided according to the invention novel compounds of formula (I) wherein R , R , and R are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives

Growing community of inventors

Stevenage, United Kingdom

Alison Judith Redgrave